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Abstract
Background: Amyloid p40 (Ap40) is the most abundant Ap peptide in the brain. The cerebrospinal 
fluid (CSF) level of Ap40 might therefore be considered to most closely reflect the total Ap load in the 
brain. Both in Alzheimer’s disease (AD) and in normal aging the Ap load in the brain has a large inter­
individual variability. Relating Ap42 to Ap40 levels might consequently provide a more valid measure 
for reflecting the change in Ap metabolism in dementia patients than the CSF Ap42 concentrations 
alone. This measure may also improve differential diagnosis between AD and other dementia 
syndromes, such as vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal 
dementia (FTD).
Objective: To investigate the diagnostic value of the CSF Ap42/Ap40 ratio in differentiating AD from 
controls, VaD, DLB and FTD.
Methods: We analysed the CSF Ap42/Ap40 ratio, phosphorylated tau181 and total tau in 69 patients with 
AD, 26 patients with VaD, 16 patients with DLB, 27 patients with FTD, and 47 controls.
Results: Mean Ap40 levels were 2850 pg/ml in VaD and 2830 pg/ml in DLB patients, both 
significantly lower than in AD patients (3698 pg/ml; p<0.01). Ap40 levels in AD patients were not 
significantly different from those in controls (4035 pg/ml; p=0.384). The Ap42/Ap40 ratio was 
significantly lower in AD patients than in all other groups (p <0.001, ANCOVA). Differentiating AD 
from VaD, DLB and non-AD dementia improved when the Ap42/Ap40 ratio was used instead of Ap42 
concentrations alone (p<0.01) The Ap42/Ap40 ratio performed equally well as the combination of Ap42, 
phosphorylated tau181 and total tau in differentiating AD from FTD and non-AD dementia. The 
diagnostic performance of the latter combination was not improved when the Ap42/Ap40 ratio was used 
instead of Ap42 alone.
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Conclusion: The CSF Aß42/Aß4o ratio improves differentiation of AD patients from VaD, DLB and 
non-AD dementia patients, when compared to Aß42 alone, and is a more easily interpretable alternative 
to the combination of Aß42, p-tau and t-tau when differentiating AD from either FTD or non- AD 
dementia.
Key words: Abeta40 protein, Aß42/Aß40 ratio, Alzheimer’s disease, vascular dementia, dementia with 
Lewy bodies.
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Introduction
While making an accurate diagnosis is important for management of dementia, differentiating between 
Alzheimer’s disease (AD) and other types of dementia using clinical criteria is the true clinical 
challenge: difficult and prone to inaccuracy. The NINCDS-ADRDA criteria for AD[1] have been 
validated against neuropathological standards and turned out to have a specificity of 23-69% for 
differentiating AD from other dementias.[2, 3]
Analysis of cerebrospinal fluid (CSF) has been used increasingly to differentiate the various 
dementia disorders.[4] Although CSF analysis of amyloid ß42 (Aß42), phosphorylated tau181 (p-tau181) 
and total tau (t-tau) is efficacious in distinguishing between AD dementia and non-demented controls, 
it is inaccurate in separating AD from other types of dementia.[5-7] CSF biomarker profiles of AD, 
vascular dementia (VaD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB) 
overlap, which makes discrimination between these various dementias based on CSF analysis alone 
difficult.
It has been suggested that relating Aß42 to the concentration of Aß40 may improve diagnostic 
accuracy of CSF analysis.[8] Aß40 is the most abundant Aß peptide in human CSF, whereas Aß42 
accounts for only 10% of the total Aß population.[6, 9-11] As such, CSF Aß40 concentrations could be 
considered as the closest possible reflection of the total Aß load in the brain. This total CSF Aß load 
shows a large inter-individual variability.[12] Patients with a low total Aß load and therefore a low 
CSF Aß42 concentration [11], might receive an inappropriate diagnosis of AD if only CSF Aß42 is 
considered and an absolute cut-off value is used. Similarly, in patients with AD but with a high total 
Aß load, CSF Aß42 concentrations may not decrease below the cut-off value and in those cases 
rejection of the diagnosis AD might be incorrect. Since the total Aß concentration was found not to 
change in various dementia disorders,[8, 10, 13] and Aß40 concentrations were shown to be similar in 
groups of AD patients, controls and non-AD dementia patients,[13-17] hypothetically the ratio of Aß42 
to Aß40 reflects the Aß changes in the brain more accurately than Aß42 alone.
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It was found in several studies that differentiation between AD and healthy controls, subjects 
with non-AD dementia, or subjects with other neurological disorders, improved when using the CSF 
Aß42/Aß40 ratio compared to Aß42 alone,[15, 17, 18] although these results were not confirmed in other 
studies.[19, 20] The Aß42/Aß40 ratio has previously been studied in patients with FTD and AD, and a 
significantly decreased Aß40 was found in FTD patients, resulting in an increased Aß42/Aß40 ratio 
compared to AD patients.[21] In a recent review it was concluded that levels of CSF Aß40 or Aß42 
cannot usefully discriminate between AD and DLB,[22] although one study found that the Aß42/Aß40 
ratio improved diagnostic accuracy of AD versus DLB relative to Aß42 alone.[23] To our knowledge, 
the Aß42/Aß40 ratio has not been investigated in relation to VaD.
We hypothesized that differentiation between dementia syndromes would improve by using 
the CSF Aß42/Aß40 ratio since it may eliminate inter-individual differences in total Aß load. Therefore, 
we explored the CSF Aß40 concentration and Aß42/Aß40 ratio in patients with AD, VaD, DLB, FTD 
and in controls, and we investigated the diagnostic value of the Aß42/Aß40 ratio in differentiating AD 
from each of these groups individually as well as from the total group of non-AD dementia patients.
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Materials and methods
Patients
Sixty-nine AD, 26 VaD, 27 FTD, and 16 DLB patients were included in this study that was based on 
the CSF database of the Alzheimer Centre of the Radboud University Nijmegen Medical Centre. This 
database contains clinical data as well as biobanked CSF and serum of consecutive patients. All 
patients or their legal representative had given informed consent for lumbar puncture. We included all 
patients with a clinically clear-cut dementia diagnosis, whose CSF was available for Ap40 and Ap42 
analysis. Data on t-tau and p-tau181 were also obtained. A diagnosis was made by a multidisciplinary 
team, which consisted of a geriatrician, neurologist, neuropsychologist, and -  if needed -  an old-age 
psychiatrist. The panel used the accepted clinical diagnostic criteria, i.e. the NINCDS-ADRDA criteria 
for probable AD, the NINDS-AIREN criteria for probable VaD, the 1998 consensus on clinical 
diagnostic criteria for FTD and the 1996 consensus guidelines for the clinical and pathologic diagnosis 
of DLB.[1, 24-26] In less than 10% of the cases, the clinicians were aware of the CSF results for Ap42, 
p-tau181 and t-tau when establishing the clinical diagnosis, but they were never aware of Ap40 levels.
The control group consisted of 47 non-demented patients who underwent lumbar puncture for 
various complaints. Most frequently diagnosed were headache (n=10), polyneuropathy (n=5), 
radiculopathy (n=4), vertigo (n=3), and delirium (n=2). The remaining controls had a variety of 
complaints but turned out not to have central neurological problems. CSF cell count, glucose, lactate, 
haemoglobin, bilirubin, total protein and oligoclonal IgG bands were normal in all controls. Patient 
characteristics are listed in table 1.
CSF
CSF was collected by lumbar puncture in polypropylene tubes, transported within 30 minutes to the 
adjacent laboratory at room temperature, centrifuged after routine investigations, and immediately 
aliquoted and stored at -80 °C until analysis. Levels of Ap42, t-tau, and p-tau181 in CSF were measured 
using enzyme linked immunosorbent assays (Innogenetics NV, Gent, Belgium). Inter-assay
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coefficients of variation for these assays were 3.8 -  8.4%.[27] CSF Ap40 was analysed by using a 
commercial assay based on the Luminex technology (BioSource, Invitrogen Ltd, Paisley, UK). Inter­
assay coefficient of variation for Ap40 was 5.4 % (at 2875 pg/ml; n=32). The lower limit of detection 
was for Ap42 50 pg/ml and for Ap40 22 pg/ml.
Statistical analysis
Since p-tau181, t-tau, Ap42, Ap40, and the Ap42/Ap40 ratio were not all normally distributed, they were 
log-transformed. Differences in p-tau181, t-tau, Ap42, Ap40 and the Ap42/Ap40 ratio were analysed using 
2-way ANCOVA. Since sex and age did not contribute to the differences in Ap42, Ap40 and the 
Ap42/Ap40 ratio between dementia groups and controls, both (sex and age) were removed from the 
model and the ANCOVA was thereafter rerun. Differences between AD and the other groups were 
further explored using Dunnett’s post-hoc test.
We used logistic regression analysis to assess the value of the Ap42/Ap40 ratio compared to 
other combinations of CSF biomarkers in differentiating AD from controls, from VaD, FTD, DLB, 
respectively, and from these three groups combined (‘non-AD dementia’). Sex and age contributed 
significantly to the logistic regression models and therefore the models were corrected for these 
factors. Receiver operating characteristic (ROC) curves were calculated and the areas under the ROC 
curves were compared using MedCalc (Mariakerke, Belgium). Sensitivity and specificity were 
determined based on the highest Youden index, i.e. the point on the ROC curve at which sensitivity + 
specificity -  1 is maximized. All other statistical analyses were carried out using SPSS, version 16.0.
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Results
Insert 
Table 1 
about 
here
Insert 
Table 2 
about 
here
The mean level of CSF Ap40 was significantly lower in VaD patients than in AD patients (p<0.001), as 
well as in DLB patients compared to AD patients (p=0.008) (see Table 1 and Fig. (1)). There was no 
significant difference in Ap40 levels between AD patients and FTD patients (p=0.981) or controls 
(p=0.384). In AD patients, the concentration of CSF Ap42 was significantly lower than in VaD and 
FTD patients and controls (p<0.001), whereas the concentration of p-tau181 and t-tau was significantly 
higher than in all other groups (p<0.001).The Ap42/Ap40 ratio was significantly lower in AD patients 
than in all other groups (p <0.001) (see Table 1 and Fig. (1)).
We investigated the diagnostic value of the Ap42/Ap40 ratio in several comparisons. First, we 
investigated if the use of the Ap42/Ap40 ratio would be superior to the use of Ap42 alone.
Differentiation of AD from either VaD, DLB or non-AD dementia significantly improved when using 
the Ap42/Ap40 ratio (p<0.01). In contrast, differentiation of AD from either FTD or controls did not 
improve (p> 0.05). Second, we analysed the diagnostic value of the Ap42/Ap40 ratio compared to the 
combination of Ap42/Ap40 ratio p-taui8i and t-tau, which is a frequently used combination of CSF 
biomarkers in AD research. Differentiation of AD from either FTD or non-AD dementia was equally 
good for the Ap42/Ap40 ratio or the combination of Ap42, p-tau181 and t-tau (p >0.05). Differentiation of 
AD from either controls, VaD or DLB was better using the combination of Ap42, p-tau181 and t-tau 
than using the Ap42/Ap40 ratio (p<0.05). Third, we analysed if replacement of Ap42 by the Ap42/Ap40 
ratio in the combination with p-tau181 and t-tau would improve results. Differentiation of AD from 
both controls and from all dementia groups was equally good for both combinations (p >0.05). ROC 
curves are shown in Fig. (2) and Fig. (3). Sensitivity and specificity, AUC and likelihood ratios of 
each parameter are shown in Table 2.
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Discussion
We explored the CSF Ap40 concentrations in patients with different types of dementia and in controls, 
and examined the value the Ap42/Ap40 ratio in differentiating AD from controls, from FTD, DLB,
VaD, and from these latter three groups combined. The observed patterns of Ap40 and Ap42 in the 
various dementia groups are remarkable. As expected, the AD group was characterized by normal 
Ap40 and low Ap42 levels, but contrary to our expectations, the VaD group had low Ap40 and 
intermediate Ap42 levels, whereas the DLB group was characterized by low concentrations of both 
Ap40 and Ap42 levels. The FTD group had normal Ap40 and Ap42 levels.
Only one study has reported the CSF Ap40 concentration in patients with VaD. In accordance 
with our results, a lower Ap40 concentration in VaD patients compared to AD patients was found.[28] 
Multiple explanations for this low Ap40 concentration are possible. For example, it may be caused by 
the ischemic damage that has occurred in VaD patients, since cerebral ischemia has been shown to 
result in plaque formation and accumulation of Ap40 and Ap42 [29-31] and, consequently, leads to a 
reduced CSF concentration. In addition, atherosclerosis, one of the risk factors for VaD, may inhibit 
the clearance of Ap40 across the blood-brain barrier, leading to vascular deposits of Ap40.[32]
Our finding of a lower Ap40 concentration in DLB patients compared to AD is in accordance 
with the literature.[12] Possibly, the intraneuronal a-synuclein aggregates that are found in DLB affect 
Ap metabolism, leading to an overall decrease in Ap synthesis. Results from in vitro research indicate 
an interaction between a-synuclein and Ap.[33, 34] Neuropathological studies found a positive 
correlation between Ap plaque burden and a-synuclein load.[35, 36] Ap40 plaque level was greater in 
cases with a-synuclein aggregates compared to cases lacking a-synuclein aggregates, while no 
difference was found in Ap42 plaque burden.[35] A greater Ap40 plaque burden in DLB might explain 
the decreased Ap40 concentration in CSF that we found.
The few studies that measured Ap40 concentration in FTD patients report varying results. Our 
results are supported by previous findings of similar concentrations of Ap40 in FTD patients and AD 
patients.[37] In contrast with this, another group reported lower Ap40 concentrations in FTD patients
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compared to AD patients.[21] The varying results might be explained by the inclusion of 
heterogeneous FTD patient groups in research, comprising patients with clinically diagnosed FTD, 
semantic dementia and primary progressive aphasia, presumably with different neuropathological 
substrates.
We investigated the Ap42/Ap40 ratio under the assumption that Ap40 closely represents the total 
cerebral Ap load. Since we found different Ap40 concentrations in the various dementia groups, it can 
be debated if the Ap42/Ap40 ratio is a good representation of the Ap42 fraction of the total Ap load and 
thus eliminates inter-individual differences in total Ap concentrations. Nevertheless, differentiating 
AD from VaD, DLB and non-AD dementia improved when we used this ratio compared to Ap42 alone, 
probably due to the differences in Ap40 concentrations. Results obtained by applying the Ap42/Ap40 
ratio fulfilled the criteria for biomarkers as established by the Working Group on molecular and 
biochemical markers of Alzheimer’s disease[38] in differentiating AD from VaD, FTD, DLB, and 
non-AD, since both sensitivity and specificity were >80%.
The Ap42/Ap40 ratio seems to be a good alternative for the combination of Ap42, p-tau181 and t- 
tau, to distinguish AD from either FTD or non-AD dementia. The Ap42/Ap40 ratio has the advantage 
that only two analyses are needed instead of three, and, consequently, the results are easier to interpret. 
The differentiation of AD from non-AD dementia is a frequently encountered problem in clinical 
practice, when dementia can be established, but the differential diagnosis encompasses AD and 
another type of dementia. Thus, the use of the CSF Ap42/Ap40 ratio may help in this clinical decision 
making. However, the use of four biomarkers, i.e. the Ap42/Ap40 ratio combined with p-tau181 and t- 
tau, did not improve differentiation when compared to the combination of the three currently used 
biomarkers Ap42, p-tau181 and t-tau.
Some bias may have occurred in our analysis since in less than 10% of the patients the results 
of the CSF analysis for Ap42, t-tau and p-tau181 were known to the clinicians. However, given the small 
fraction of patients this applies to, we believe that this did not affect our results, also since our 
sensitivity and specificity results for discriminating AD from other dementias using Ap42 are 
comparable with the literature.[18, 39, 40] The number of patients in our non-AD groups were 
moderate, yet not very different from the numbers mentioned in other studies.[12, 21, 28, 37] Besides,
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the significant results that we found had a p-value <0.01, suggesting that these results are not expected 
to change with an increasing number of patients.
In summary, the Ap42/Ap40 ratio is more accurate for differentiating AD from other types of 
dementia than Ap42 alone, and can be a good and easier interpretable alternative for the combination of 
the established biomarkers Ap42, p-taui8i and t-tau for the differentiation of AD from non-AD 
dementia, which may help to accept or refute the clinical diagnosis of AD.
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Table 1 Clinical characteristics and results of CSF analysis
controls AD VaD FTD DLB
males/females (n) 23/24 34/35 17/9 19/8 12/4
age (y) 61 ± 8 69 ± 8 72 ± 9 65 ± 7 76 ± 8
disease duration (mo) n.a. 29 ± 23 35 ± 29 34 ± 21 34 ± 27
n=60 n=20 n=26 n=8
t-tau (pg/ml)* 221 ± 80 7 1 0 ± 390 3 9 1 ± 526 4 4 8 ± 315 257 ± 98
p-taui8i (pg/ml)* 49 ± 16 111 ± 52 46 ± 16 70 ± 36 53 ± 17
AP42 (pg/ml)* 840 ± 260 428 ± 127 6 3 1 ± 270 786 ± 229 499 ± 179
*/ml)g/(po4A 4 035± 1177 3698± 1096 2850± 1031 3590± 1038 2830 ± 697
Ap42/Ap40 ratio* 0.21 ± 0.04 0.12 ± 0.04 0.23 ± 0.08 0.23 ± 0.06 0.18 ± 0.06
Values are expressed as means ± SD.
*, p-value <0.001 by ANOVA.
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with Lewy 
bodies; t-tau, total tau; p-tau181, phosphorylated tau181; n.a., not applicable
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Table 2 Sensitivities and specificities, AUC and likelihood ratios for discriminating Alzheimer’s 
disease from controls and from other types of dementia, using different combinations of CSF 
biomarkers
AD vs controls AD vs VaD AD vs FTD AD vs DLB AD vs non-AD
sens. AUC LR sens. AUC LR sens. AUC LR sens. AUC LR sens. AUC LR
spec. spec. spec. spec. spec.
AP42 93%
87%
0.949 7.3 83%
69%
0.785 2.7 94%
85%
0.941 6.4 65%
75%
0.755 2.6 83%
74%
0.811 3.2
Ap42/Ap40 ratio 93%
87%
0.947 7.3 93%
84%
0.900* 5.8 99%
83%
0.936 5.9 85%
85%
0.893* 5.5 90%
82%
0.903* 5.1
AP42, p-tau, 
t-tau
97%
98%
0.994* 45.6 93%
96%
0.963* 23.1 93%
88%
0.953 7.4 90%
100%
0.966* n.c. 93%
84%
0.924 5.7
Ap42/Ap40 ratio, 
p-tau, t-tau
93%
98%
0.980 43.5 91%
96%
0.957 22.8 99%
79%
0.936 4.7 90%
100%
0.970 n.c. 87%
90%
0.923 9.0
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with Lewy 
bodies; non-AD, combined group of patients with VaD, FTD or DLB.
Sens., sensitivity; spec., specificity; AUC, area under the ROC curve; LR, likelihood ratio; n.c., not computable.
* p<0.01 compared to AUC for Ap42 level
* p<0.05 compared to AUC for Ap42/Ap40 ratio
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Figure 1 Cerebrospinal fluid Ap42 and Ap40 concentrations and Ap42/Ap40 ratio in controls and patients
with various types of dementia
diagnosis
See text for statistical analyses.
Bold horizontal bar represents the median. Central box: 25th to 75th percentile (interquartile range). 
Vertical bar bordered by highest and lowest value within 1.5 * interquartile range.
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with 
Lewy bodies
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Figure 2 Receiver Operating Characteristic curves comparing Ap42, and the Ap42/Ap40 ratio in AD 
versus controls and versus various types of dementia
AD vs controls AD vs VaD AD vs FTD
O 20 40 60 80 100 0 20 40 60 80 100 O 20 40 60 80 lOO
100-specificity 100-specificity 100-specificity
AD vs DLB AD vs non-AD
0 20 40 60 80 100 0 20 40 60 80 100
100-specificity 100-specificity
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with 
Lewy bodies.
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Figure 3 Receiver Operating Characteristic curves comparing the Ap42/Ap40 ratio, the Ap42/Ap40 ratio 
combined with p-tau181 and t-tau, and the combination of Ap42, p-tau181 and t-tau in AD versus controls 
and versus various types of dementia
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with 
Lewy bodies.
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